Catherine Monet-Didailler, Audrey Chevallier, Astrid Godron-Dubrasquet, Lise Allard, Yahsou Delmas, Cécile Contin-Bordes, Olivier Brissaud, Brigitte Llanas, Jérôme Harambat
BACKGROUND: Treatment with eculizumab in Shiga toxin-associated haemolytic and uraemic syndrome (STEC-HUS) remains controversial despite its increasing utilization. The aim of our study was to evaluate the outcomes of children treated with eculizumab for STEC-HUS in a single-centre matched cohort study. METHODS: Data were retrospectively collected from medical records of children diagnosed with STEC-HUS. The outcomes of patients treated with eculizumab for STEC-HUS were compared with those of a control group of untreated patients matched for age, sex and severity of acute kidney injury with a 1:2 matching scheme...
December 4, 2020: Nephrology, Dialysis, Transplantation